|
Hemato-oncology
The prognostic impact of inflammatory factors in patients with multiple myeloma treated with thalidomide in Korea
Cheolsu Kim, Ho Sup Lee, Chang-Ki Min, Je Jung Lee, Kihyun Kim, Dok Hyun Yoon, Hyeon Seok Eom, Hyewon Lee, Won Sik Lee, Ho-Jin Shin, Ji Hyun Lee, Yong Park, Jae-Cheol Jo, Young Rok Do, Yeung-Chul Mun
Korean J Intern Med. 2015;30(5):675-683. Published online August 27, 2015
Background/Aims: The purpose of this study was to determine the correlations between inflammatory factors—including absolute lymphocyte count, lactate dehydrogenase, β2-microglobulin, albumin, C-reactive protein, and ferritin—and the prognosis for survival in patients with multiple myeloma (MM) ..
|
|
|
Diagnosis and therapy of multiple myeloma
Antonio Palumbo, Chiara Cerrato
Korean J Intern Med. 2013;28(3):263-273. Published online May 1, 2013
Many advances in the treatment of multiple myeloma have been made due to the use of transplantation and the introduction of novel agents including thalidomide, lenalidomide, and bortezomib. The first step is recognizing the symptoms and starting prompt treatment. Different strategies should be se..
|
|
|
A Combination of Melphalan, Prednisone, and 50 mg Thalidomide Treatment in Non-Transplant-Candidate Patients with Newly Diagnosed Multiple Myeloma
Hye Jung Chang, Jae Hoon Lee, Young Rok Do, Sung-Hwa Bae, Jung-Lim Lee, Seung Hyun Nam, Sung-Soo Yoon, Soo-Mee Bang
Korean J Intern Med. 2011;26(4):403-409. Published online November 28, 2011
Background/AimsThe clinical efficacy and safety of a three-drug combination of melphalan, prednisone, and thalidomide were assessed in patients with multiple myeloma who were not candidates for high-dose therapy as a first-line treatment. Because the side effects of thalidomid..
|
|
|
Thalidomide Induced Nonspecific Interstitial Pneumonia in Patient with Relapsed Multiple Myeloma
Myung-Hee Kang, Ji-Hyun Ju, Hoon-Gu Kim, Jung Hun Kang, Kyung-Nyeo Jeon, Ho-Cheol Kim, Gyeong-Won Lee
Korean J Intern Med. 2010;25(4):447-449. Published online November 27, 2010
A 63-year-old female diagnosed with relapsed multiple myeloma visited our hospital complaining of a persistent cough. Since July 2006, she had been taking 100 mg thalidomide daily and gradually developed shortness of breath and a persistent dry cough. A chest X-ray and computed tomography showed ..
|
|
|
Thalidomide for Treating Metastatic Hepatocellular Carcinoma: A Pilot Study
Sang Hoon Han, Se Hoon Park, Jung Ho Kim, Jong Jun Lee, So Young Kwon, Oh Sang Kwon, Sun Suk Kim, Ju Hyun Kim, Keon Kug Kim, Yeon Ho Park, Jeong Nam Lee, Eunmi Nam, Soo-Mee Bang, Eun Kyung Cho, Dong Bok Shin, Jae Hoon Lee
Korean J Intern Med. 2006;21(4):225-229. Published online December 31, 2006
BackgroundThalidomide has been reported to have antitumor activity for treating metastatic hepatocellular carcinoma (HCC). We evaluated the safety and efficacy of using thalidomide for treating selected patients with unresectable or metastatic HCC, and their disease was refrac..
|
|
|
